Increased incidence of matrix metalloproteinases in urine of cancer patients

Cancer Research

Volumn 58, Issue 7, 1998, Pages 1395-1399

  Moses, Marsha A ^a,d   Wiederschain, Dmitri ^a   Loughlin, Kevin R ^b,d   Zurakowski, David ^a,d   Lamb, Carolyn C ^c,d   Freeman, Michael R ^a,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYMURIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; URINALYSIS; URINARY TRACT CANCER;

EID: 0032054579     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., and Folkman, J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. Natl. Cancer Inst. (Bethesda), 85: 241-242, 1993.
2. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F., and Folkman, J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancer. J. Natl. Cancer Inst. (Bethesda), 86: 356-361, 1994.
3. r 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res., 53: 5802-5807, 1993.
4. Garbisa, S., Scagliotti, G., Masiero, L., Di Francesco, C., Caenazzo, C., Onisto, M., Micela, M., Stetler-Stevenson, W. G., and Liotta, L. A. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res., 52: 4548-4549, 1992.
5. Baker, T., Tickle, S., Wasan, H., Docherty, A., Isenberg, D., and Waxman, J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br. J. Cancer, 70: 506-512, 1994.
6. r 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res., 53: 140-146, 1993.
7. Gohji, K., Fujimoto, N., Fujii, A., Komiyama, T., Okawa, J., and Nakajima, M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res., 56: 3196-3198, 1996.
8. Gohji, K., Fujimoto, N., Komiyama, T., Fujii, A., Okawa, J., Kamidono, S., and Nakajima, M. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer (Phila.), 78: 2379-2387, 1996.
9. Herron, G. S., Banda, M. J., Clark, E. J., Gavrilovic, J., and Werb, Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J. Biol. Chem., 261: 2814-2828, 1986.
10. Braunhut, S. J., and Moses, M. A. Retinoids modulate endothelial cell production of matrix-degrading proteases and TIMPs. J. Biol. Chem., 269: 13472-13479, 1994.
11. Blyth, C. R. Approximate binomial confidence limits. J. Am. Stat. Assoc., 81: 843-855, 1986.
12. Weinstein, M. C., and Fineberg, H. V. (eds.). Clinical Decision Analysis, pp. 84-108. Philadelphia: W. B. Saunders, Co., 1980.
13. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research. I. The Analysis of Case-Control Studies, pp. 192-210. Lyon, France: IARC, 1980.
14. Woessner, J. F. The family of matrix metalloproteinases. Ann. N. Y. Acad. Sci., 732: 11-21, 1994.
15. Margulies, I. M., Hoyhtya, M., Evans, C., Stracke, M. L., Liotta, L. A., and Stetler-Stevenson, W. G. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol. Biomark. Prev., 1: 467-474, 1992.
16. Howard, E. W., Bullen, E. C., and Banda, M. J. Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinase-2. J. Biol. Chem., 266: 13064-13069, 1991.
17. Prestigiacomo, A. F., Lilja, H., Pettersson, K., Wolfert, R. L., and Stamey, T. A.,. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates. J. Urol., 156: 350-354, 1996.
18. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., and Tangen, C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. J. Am. Med. Assoc., 270: 943-947, 1993.
19. Berek, J. S., and Bast, R. C., Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer (Phila.), 76: 2092-2096, 1995.
20. Greenhalgh, T. Papers that report diagnostic or screening tests. Br. Med. J., 315: 540-543.